Opinion|Videos|January 17, 2025
MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas
Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing epcoritamab and glofitamab that may influence therapy selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you use comparative data from MAIC analyses to guide treatment decisions between available bispecific therapies?
- What do the results of the MAIC comparing epcoritamab and glofitamab suggest about the relative differences of these agents, and how might these influence therapy selection?
Advertisement
Related to this article
Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
4
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
5